SCHEDULE 13D/A: Mangoceuticals Insider Jacob Cohen Boosts Stake to 11% Following Significant Stock Bonus

Jacob D. Cohen and The Tiger Cub Trust have updated their beneficial ownership in Mangoceuticals, Inc., with Mr. Cohen receiving a 200,000-share bonus, increasing his aggregate stake to 11.0%.

Summary

• Jacob D. Cohen and The Tiger Cub Trust have filed Amendment No. 4 to their Schedule 13D, updating their beneficial ownership in Mangoceuticals, Inc.
• As of April 10, 2025, Jacob D. Cohen beneficially owns an aggregate of 921,666 shares of Mangoceuticals common stock, representing 11.0% of the outstanding shares.
• This includes 83,333 shares issuable from options at $4.80 (expiring December 28, 2028) and 33,333 shares from options at $16.50 (expiring August 31, 2027), which are vested or vest within 60 days of April 10, 2025.
• The Tiger Cub Trust beneficially owns 605,000 shares, representing 7.3% of the outstanding shares, with shared voting and dispositive power with Mr. Cohen.
• On April 10, 2025, the Company issued 200,000 fully-vested shares to Mr. Cohen as a discretionary bonus for services rendered in 2025, approved by the Board and Compensation Committee under the 2022 Equity Plan.
• The percentage ownership is based on 8,268,240 shares of Common Stock outstanding as of April 10, 2025, as confirmed by the Issuer's transfer agent.
• A 1-for-15 reverse stock split was effected on October 16, 2024, and is reflected in the disclosures throughout this Amendment.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily a factual disclosure of beneficial ownership and a stock bonus. The bonus to a key insider could be seen as positive for alignment, but the filing itself doesn't convey strong positive or negative sentiment about the company's performance.

Positives

• Jacob D. Cohen received a significant discretionary bonus of 200,000 fully-vested shares, indicating recognition for his services.
• The bonus was approved by the Compensation Committee and the Board of Directors, suggesting formal corporate governance processes were followed.
• Mr. Cohen's increased beneficial ownership to 11.0% could signal strong insider confidence in the company's future.

Negatives

• The issuance of 200,000 shares as a bonus could lead to minor dilution for existing shareholders, although the impact on the overall share count is relatively small given the 8.26 million shares outstanding.

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the disclosure of existing stock options with future expiration dates.

Industry Context

This Schedule 13D amendment primarily concerns changes in beneficial ownership by a significant insider and related entities. It does not provide broader industry context or analysis of Mangoceuticals' position relative to industry trends or competitors.

Corporate Governance

Related Party Transactions

• The issuance of 200,000 fully-vested shares to Jacob D. Cohen, a reporting person and likely an executive or director, as a discretionary bonus for services rendered, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of 200,000 bonus shares, but also a signal of insider confidence and retention of key personnel. The reverse stock split impacts share count and price per share but not overall value.
• Employees: The bonus to Mr. Cohen, if he is an employee, could be seen as a positive for employee morale regarding performance recognition, though it's a specific executive bonus.

Next Steps

• Continued operation under the Second Amended and Restated Mangoceuticals, Inc. 2022 Equity Plan.
• Future disclosures of beneficial ownership changes as required by SEC regulations.

Key Dates

Keywords

Mangoceuticals Inc., Jacob D. Cohen, The Tiger Cub Trust, Schedule 13D, Beneficial Ownership, Stock Bonus, Reverse Stock Split, Insider Ownership, Equity Plan, SEC Filing